Stemline Therapeutics Stock Price, News & Analysis (NASDAQ:STML)

$13.45 0.00 (0.00 %)
(As of 01/18/2018 04:52 AM ET)
Previous Close$13.45
Today's Range$13.24 - $13.65
52-Week Range$5.50 - $16.20
Volume116,100 shs
Average Volume193,727 shs
Market Capitalization$337.45 million
P/E Ratio-5.23
Dividend YieldN/A
Beta-0.02

About Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:STML
CUSIPN/A
Phone+1-646-5022310

Debt

Debt-to-Equity RatioN/A
Current Ratio4.57%
Quick Ratio4.57%

Price-To-Earnings

Trailing P/E Ratio-5.23346303501946
Forward P/E Ratio-4.96
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.04 million
Price / Sales327.07
Cash FlowN/A
Price / CashN/A
Book Value$2.44 per share
Price / Book5.51

Profitability

Trailing EPS($2.57)
Net Income$-38,300,000.00
Net Margins-4,689.63%
Return on Equity-75.50%
Return on Assets-64.20%

Miscellaneous

Employees29
Outstanding Shares25,290,000

Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.11. Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. View Stemline Therapeutics' Earnings History.

When will Stemline Therapeutics make its next earnings announcement?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Stemline Therapeutics.

Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2018?

5 analysts have issued 1 year target prices for Stemline Therapeutics' shares. Their predictions range from $16.00 to $41.00. On average, they expect Stemline Therapeutics' share price to reach $33.75 in the next year. View Analyst Ratings for Stemline Therapeutics.

What are Wall Street analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:

  • 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (1/5/2018)
  • 2. HC Wainwright analysts commented, "Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year." (5/15/2017)
  • 3. Cowen Inc analysts commented, "STML reported 1Q17 financials and provided a pipeline update." (5/12/2017)

Who are some of Stemline Therapeutics' key competitors?

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the folowing people:

  • Ivan Bergstein M.D., Chairman of the Board, President, Chief Executive Officer (Age 51)
  • Kenneth Hoberman, Chief Operating Officer (Age 52)
  • David G. Gionco, Chief Accounting Officer, Vice President - Finance (Age 56)
  • Ron Bentsur, Independent Director (Age 51)
  • Eric L. Dobmeier, Independent Director (Age 48)
  • Alan S. Forman, Independent Director (Age 51)
  • Kenneth J. Zuerblis, Independent Director (Age 58)

Who owns Stemline Therapeutics stock?

Stemline Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.19%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.

Who bought Stemline Therapeutics stock? Who is buying Stemline Therapeutics stock?

Stemline Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Stemline Therapeutics.

How do I buy Stemline Therapeutics stock?

Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of Stemline Therapeutics stock can currently be purchased for approximately $13.45.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $337.45 million and generates $1.04 million in revenue each year. The biopharmaceutical company earns $-38,300,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. Stemline Therapeutics employs 29 workers across the globe.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 Lexington Ave, NEW YORK, NY 10022-1200, United States. The biopharmaceutical company can be reached via phone at +1-646-5022310 or via email at [email protected]


MarketBeat Community Rating for Stemline Therapeutics (STML)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Stemline Therapeutics (NASDAQ:STML) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.75$33.75$32.60$32.60
Price Target Upside: 115.65% upside115.65% upside232.65% upside326.14% upside

Stemline Therapeutics (NASDAQ:STML) Consensus Price Target History

Price Target History for Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics (NASDAQ:STML) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017HC WainwrightSet Price TargetBuy$38.00HighView Rating Details
10/31/2017CowenReiterated RatingBuyN/AView Rating Details
5/25/2017Jefferies GroupReiterated RatingBuy$16.00MediumView Rating Details
5/11/2017WedbushBoost Price TargetOutperform$33.00 -> $40.00HighView Rating Details
3/20/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$41.00MediumView Rating Details
12/7/2016Roth CapitalReiterated RatingBuy$32.00N/AView Rating Details
3/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Stemline Therapeutics (NASDAQ:STML) Earnings History and Estimates Chart

Earnings by Quarter for Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics (NASDAQ STML) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.70)N/AView Earnings Details
11/9/2017Q3 2017($0.57)($0.68)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.48)($0.66)$0.30 million$0.30 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.45)($0.67)$0.30 million$0.30 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.55)($0.56)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.53)($0.56)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.54)($0.52)ViewN/AView Earnings Details
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)$0.15 million$0.21 millionViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)$0.10 million$0.21 millionViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)$0.10 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q1($0.45)($0.46)$0.09 million$0.12 millionViewN/AView Earnings Details
3/13/2015($0.60)($0.53)$0.07 million$0.12 millionViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)$0.07 million$0.07 millionViewN/AView Earnings Details
8/14/2014($0.71)($0.47)$0.07 million$0.07 millionViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.45)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.90)ViewN/AView Earnings Details
4/1/2013Q4 2012($0.38)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Stemline Therapeutics (NASDAQ:STML) Earnings Estimates

2018 EPS Consensus Estimate: ($2.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.54)($0.54)($0.54)
Q3 20181($0.55)($0.55)($0.55)
Q4 20181($0.53)($0.53)($0.53)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Stemline Therapeutics (NASDAQ STML) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.70%
Institutional Ownership Percentage: 50.24%
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics (NASDAQ STML) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/8/2018Kenneth HobermanCOOSell14,040$13.93$195,577.20View SEC Filing  
12/18/2017Kenneth HobermanCOOSell11,983$14.18$169,918.94View SEC Filing  
12/15/2017Kenneth HobermanCOOSell11,943$14.18$169,351.74View SEC Filing  
2/28/2017David GioncoInsiderSell6,486$6.99$45,337.14View SEC Filing  
2/28/2017Ivan BergsteinCEOSell17,980$6.99$125,680.20View SEC Filing  
2/28/2017Kenneth HobermanCOOSell8,027$6.99$56,108.73View SEC Filing  
2/27/2017David GioncoCAOSell3,500$6.97$24,395.00View SEC Filing  
2/27/2017Ivan BergsteinCEOSell7,500$6.97$52,275.00View SEC Filing  
2/27/2017Kenneth HobermanCOOSell4,000$6.97$27,880.00View SEC Filing  
2/16/2017Ivan BergsteinCEOSell3,652$6.42$23,445.84View SEC Filing  
2/16/2017Kenneth HobermanCOOSell1,508$6.42$9,681.36View SEC Filing  
1/19/2017David GioncoInsiderSell3,593$11.46$41,175.78View SEC Filing  
1/10/2017Kenneth HobermanCOOSell9,110$13.82$125,900.20View SEC Filing  
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36106,467View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.581,846,128View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08297,392View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.9435,244View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.001,926,826View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Stemline Therapeutics (NASDAQ STML) News Headlines

Source:
DateHeadline
Stemline Therapeutics (STML) and Mersana Therapeutics (MRSN) Financial ComparisonStemline Therapeutics (STML) and Mersana Therapeutics (MRSN) Financial Comparison
www.americanbankingnews.com - January 13 at 7:28 PM
Stemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 14,040 SharesStemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 14,040 Shares
www.americanbankingnews.com - January 13 at 12:14 AM
Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STMLNewman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML
finance.yahoo.com - January 8 at 3:34 PM
Zacks Investment Research Upgrades Stemline Therapeutics (STML) to "Hold"Zacks Investment Research Upgrades Stemline Therapeutics (STML) to "Hold"
www.americanbankingnews.com - January 5 at 12:04 PM
Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceStemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:59 AM
Stemline Therapeutics (STML) Rating Increased to Hold at ValuEngineStemline Therapeutics (STML) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - January 1 at 9:58 AM
Stemline Therapeutics (STML) vs. Its Competitors Head to Head AnalysisStemline Therapeutics (STML) vs. Its Competitors Head to Head Analysis
www.americanbankingnews.com - December 29 at 11:30 PM
Stemline Therapeutics (STML) Upgraded to Hold by BidaskClubStemline Therapeutics (STML) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - December 29 at 6:32 AM
ETFs with exposure to Stemline Therapeutics, Inc. : December 26, 2017ETFs with exposure to Stemline Therapeutics, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:49 PM
Stemline Therapeutics Inc (STML) Given Consensus Recommendation of "Hold" by AnalystsStemline Therapeutics Inc (STML) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 26 at 4:13 AM
Stemline Therapeutics (STML) & Its Rivals Financial ContrastStemline Therapeutics (STML) & Its Rivals Financial Contrast
www.americanbankingnews.com - December 26 at 1:10 AM
Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:09 PM
Stemline Therapeutics (STML) Downgraded by BidaskClub to SellStemline Therapeutics (STML) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - December 22 at 1:02 PM
Kenneth Hoberman Sells 11,983 Shares of Stemline Therapeutics, Inc. (STML) StockKenneth Hoberman Sells 11,983 Shares of Stemline Therapeutics, Inc. (STML) Stock
www.americanbankingnews.com - December 19 at 9:20 PM
Stemline Therapeutics, Inc. (STML) COO Sells $169,351.74 in StockStemline Therapeutics, Inc. (STML) COO Sells $169,351.74 in Stock
www.americanbankingnews.com - December 19 at 9:20 PM
Contrasting Stemline Therapeutics (STML) and AVEO Pharmaceuticals (AVEO)Contrasting Stemline Therapeutics (STML) and AVEO Pharmaceuticals (AVEO)
www.americanbankingnews.com - December 15 at 9:32 PM
Wedbush Weighs in on Stemline Therapeutics, Inc.s FY2019 Earnings (STML)Wedbush Weighs in on Stemline Therapeutics, Inc.'s FY2019 Earnings (STML)
www.americanbankingnews.com - December 14 at 8:26 PM
Stemline Therapeutics (STML) Given a $38.00 Price Target at HC WainwrightStemline Therapeutics (STML) Given a $38.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 14 at 7:46 PM
Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCNStemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN
www.nasdaq.com - December 13 at 9:42 AM
Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatmentStemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment
finance.yahoo.com - December 13 at 9:42 AM
Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting - NasdaqStemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting - Nasdaq
www.nasdaq.com - December 10 at 9:32 AM
Stemline Therapeutics (STML) Announces Four SL-401 Presentations at ASH MeetingStemline Therapeutics (STML) Announces Four SL-401 Presentations at ASH Meeting
www.streetinsider.com - December 8 at 9:47 AM
Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH MeetingStemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting
feeds.benzinga.com - December 8 at 7:43 AM
Stemline Therapeutics (STML) Downgraded by BidaskClubStemline Therapeutics (STML) Downgraded by BidaskClub
www.americanbankingnews.com - December 7 at 10:32 PM
Stemline Therapeutics, Inc. (STML) Given Average Rating of "Buy" by AnalystsStemline Therapeutics, Inc. (STML) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 1 at 5:59 AM
Kite Pharma (KITE) versus Stemline Therapeutics (STML) Head to Head ReviewKite Pharma (KITE) versus Stemline Therapeutics (STML) Head to Head Review
www.americanbankingnews.com - November 17 at 7:22 AM
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)
feeds.benzinga.com - November 16 at 7:49 AM
Stemline Therapeutics, Inc. (STML) Stock Rating Reaffirmed by HC WainwrightStemline Therapeutics, Inc. (STML) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 12 at 12:58 AM
Ophthotech Corporation (OPHT) vs. Stemline Therapeutics (STML) Head-To-Head ContrastOphthotech Corporation (OPHT) vs. Stemline Therapeutics (STML) Head-To-Head Contrast
www.americanbankingnews.com - November 10 at 3:40 AM
Stemline Therapeutics Reports Third Quarter 2017 Financial ResultsStemline Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 7:12 PM
Stemline Therapeutics reports 3Q lossStemline Therapeutics reports 3Q loss
finance.yahoo.com - November 9 at 7:12 PM
Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in OctoberHere's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
finance.yahoo.com - November 7 at 11:22 AM
Heres Why Stemline Therapeutics Inc. Jumped 23% Higher in OctoberHere's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
www.fool.com - November 6 at 12:36 PM
Stemline Therapeutics, Inc. (STML) Given Consensus Rating of "Buy" by BrokeragesStemline Therapeutics, Inc. (STML) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 3:46 AM
ETFs with exposure to Stemline Therapeutics, Inc. : November 2, 2017ETFs with exposure to Stemline Therapeutics, Inc. : November 2, 2017
finance.yahoo.com - November 4 at 10:54 PM
Stemline Therapeutics (STML) Phase 2 Trial of SL-401 in BPDCN Meets Primary EndpointStemline Therapeutics (STML) Phase 2 Trial of SL-401 in BPDCN Meets Primary Endpoint
www.streetinsider.com - November 2 at 9:21 AM
Stemline Therapeutics, Inc. (STML) Price Target Raised to $38.00Stemline Therapeutics, Inc. (STML) Price Target Raised to $38.00
www.americanbankingnews.com - November 1 at 11:04 AM
FDAs Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks - PR Newswire (press release)FDA's Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks - PR Newswire (press release)
www.prnewswire.com - November 1 at 9:17 AM
Noteworthy Tuesday Option Activity: SHLD, AMBA, STML - NasdaqNoteworthy Tuesday Option Activity: SHLD, AMBA, STML - Nasdaq
www.nasdaq.com - November 1 at 9:17 AM
The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% - Motley FoolThe Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% - Motley Fool
www.fool.com - November 1 at 9:17 AM
Stemline Announces Four SL-401 Presentations at Upcoming ASH MeetingStemline Announces Four SL-401 Presentations at Upcoming ASH Meeting
finance.yahoo.com - November 1 at 9:17 AM
The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%
www.fool.com - October 31 at 4:56 PM
Stemline Therapeutics (STML) "Buy" Rating Reiterated at Cowen and CompanyStemline Therapeutics' (STML) "Buy" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - October 31 at 3:25 PM
Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary EndpointStemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint
finance.yahoo.com - October 31 at 10:02 AM
Stemline Therapeutics, Inc. (STML) Scheduled to Post Quarterly Earnings on MondayStemline Therapeutics, Inc. (STML) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:36 AM
Stemline Therapeutics, Inc. (STML) Given Average Recommendation of "Buy" by BrokeragesStemline Therapeutics, Inc. (STML) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 4:46 AM
Stemline Therapeutics Stock Sees Short Interest Drop 17%Stemline Therapeutics Stock Sees Short Interest Drop 17%
www.thestreet.com - October 11 at 3:29 PM
Biotechs Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)Biotech's Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)
www.prnewswire.com - September 20 at 9:37 AM
Biotechs Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)Biotech's Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)
www.prnewswire.com - September 20 at 9:37 AM
Stemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)Stemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
www.globenewswire.com - September 20 at 9:37 AM

SEC Filings

Stemline Therapeutics (NASDAQ:STML) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Stemline Therapeutics (NASDAQ:STML) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Stemline Therapeutics (NASDAQ STML) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.